91̽»¨

Most cancer stories follow the same arc: caught late, treated hard, outcome uncertain. The thing that changes survival rates more than almost any other variable is how early the disease gets found. That is the problem a growing cluster of European AI startups has decided to go after, and the investment community is starting to take notice.

The most recent indication of this came from Paris-based SquareMind, which has raised $18 million including a previously undisclosed pre-Series A. Its Swan robot uses a robotic arm to capture standardised, full-body dermoscopic images in minutes. The round included investment from Sonder Capital, co-founded by Fred Moll, one of the most credentialed names in medical device investment globally.

Moll co-founded Intuitive Surgical, the company behind the da Vinci surgical robot, and his involvement in a round is a clear indicator about where serious capital thinks AI diagnostics is heading.

Meet The Robot That Reads Your Skin

Swan hands the final call to the dermatologist and handles the volume problem they can’t.

This is a tool that makes dermatologists considerably better at their jobs. The robot captures high-resolution images of the entire skin surface in a standardised format, and the accompanying AI software tracks new or changing lesions over time, flagging anything that looks different from a previous scan. The clinical decision stays with the doctor, but the AI handles the volume and consistency problem that makes full-body skin checks so difficult to do well at scale.

Skin cancer is one of the most common cancers globally, and one of the most treatable when caught early. The challenge is that a thorough dermoscopic examination of the full body surface is time-consuming, difficult to standardise and almost impossible to repeat consistently across multiple appointments.

Swan addresses all three of those problems simultaneously, which is why the clinical case for a tool like this is relatively straightforward even before you get to the AI.

Europe’s AI Diagnostics Moment

A lineup of European startups is pursuing similar problems across different cancer types and imaging modalities.

Spain’s Sycai Medical uses AI to analyse abdominal imaging for early-stage pancreatic and liver cancers, two of the most notoriously difficult cancers to catch before they become untreatable. Estonia’s Better Medicine focuses on high-precision imaging for internal tumours. Orakl Oncology, meanwhile, uses AI to build tumour avatar models for drug discovery, helping researchers test treatments on digital replicas before using them on patients.

What these companies share is a focus on the moment before the diagnosis is made, rather than the treatment that follows. The clinical and commercial case for catching cancer at stage one rather than stage three is overwhelming, and AI’s ability to analyse imaging at a consistency and speed that human review struggles to match makes it a natural fit for this part of the pathway.

Europe’s particular strengths in this space come from its combination of deep engineering talent, strong academic medical research infrastructure and a healthcare environment that places greater emphasis on prevention. Europe’s regulatory environment helps too, through the EU AI Act and the Medical Device Regulation, that forces companies to build safety and explainability into their products from the ground up rather than bolting it on after the fact.
That constraint turns out to be an advantage when selling into hospital systems and clinical buyers who need to trust the tool before they will use it.

What The Smart Money Is Saying

Sonder Capital’s investment thesis is instructive in this.
The firm targets transformational medical device innovations with the potential to reach billion-dollar market valuations. Its involvement in SquareMind suggests it views AI diagnostics as an emerging standard of care rather than a speculative technology bet that hospitals and healthcare systems will need to adopt at scale. This reflects a shift in how institutional investors are approaching the sector.

For anyone building in European HealthTech, the SquareMind raise is a useful reference point. It suggests that the combination of clinical rigour, AI capability and a clearly defined diagnostic problem can attract the kind of investment that historically went to US companies. The fact that Sonder Capital, a firm with deep roots in Silicon Valley medical devices, is backing a Parisian startup reflects where the interesting work in this space is being done right now.

Early detection has always been the most powerful intervention in cancer care. AI is making it scalable for the first time, and the money is following.